Randomized Phase III Trail of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naive Korean Patients with Extensive-Disease Small Cell Lung Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Kim, Hoon-Gu | - |
dc.contributor.author | Kim, Joo-Hang | - |
dc.contributor.author | Park, Keunchil | - |
dc.contributor.author | Kim, Hoon-Kyo | - |
dc.contributor.author | Jang, Joung Soon | - |
dc.contributor.author | Kim, Bong-Seog | - |
dc.contributor.author | Kang, Jin-Hyoung | - |
dc.contributor.author | Lee, Kyung Flee | - |
dc.contributor.author | Kim, Sang-We | - |
dc.contributor.author | Ryoo, Hun Mo | - |
dc.contributor.author | Kim, Jin-Soo | - |
dc.contributor.author | Lee, Ki Hyeong | - |
dc.contributor.author | Kwon, Jung Hye | - |
dc.contributor.author | Choi, Jin-Hyuk | - |
dc.contributor.author | Shin, Sang Won | - |
dc.contributor.author | Hahn, Seokyung | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.date.accessioned | 2022-12-26T15:17:15Z | - |
dc.date.available | 2022-12-26T15:17:15Z | - |
dc.date.issued | 2019-01 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.issn | 2005-9256 | - |
dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/9583 | - |
dc.description.abstract | Purpose This randomized phase III study was designed to compare the efficacy and safety of irinotecan plus cisplatin (IP) over etoposide plus cisplatin (EP) in Korean patients with extensive-disease small-cell lung cancer (SCLC). Materials and Methods Patients were randomly assigned to receive IP, composed of irinotecan 65 mg/m(2) intravenously on days 1 and 8+cisplatin 70 mg/m(2) intravenously on day 1 every 3 weeks, or EP, composed of etoposide 100 mg/m(2) intravenously on days 1, 2, 3+cisplatin 70 mg/m(2) intravenously on day 1, every 3 weeks for a maximum of six cycles, until disease progression, or until unacceptable toxicity occurred. The primary endpoint was overall survival. Results A total of 362 patients were randomized to IP (n=173) and EP (n=189) arms. There were no significant differences between IP and EP arms for the median overall survival (10.9 months vs. 10.3 months, p=0.120) and the median progression-free survival (6.5 months vs. 5.8 months, p=0.115). However, there was a significant difference in response rate (62.4% vs. 48.2%, p=0.006). The pre-planned subgroup analyses showed that IP was associated with longer overall survival in male (11.3 months vs. 10.1 months, p=0.036), <65 years old (12.7 months vs. 11.3 months, p=0.024), and Eastern Cooperative Oncology Group performance status 0/1 (12.4 months vs. 10.9 months, p=0.040) patient groups. The severity of treatment-related adverse events such as grade 3/4 anemia, nausea and diarrhea was more frequent in patients treated with IP. Conclusion The IP chemotherapy did not significantly improve the survival compared with EP chemotherapy in Korean patients with extensive-disease SCLC. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.title | Randomized Phase III Trail of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naive Korean Patients with Extensive-Disease Small Cell Lung Cancer | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.4143/crt.2018.019 | - |
dc.identifier.scopusid | 2-s2.0-85051509330 | - |
dc.identifier.wosid | 000455439600013 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, v.51, no.1, pp 119 - 127 | - |
dc.citation.title | CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 51 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 119 | - |
dc.citation.endPage | 127 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002430542 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | ETOPOSIDE/CISPLATIN | - |
dc.subject.keywordPlus | PHARMACOGENETICS | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordAuthor | Etoposide | - |
dc.subject.keywordAuthor | Irinotecan | - |
dc.subject.keywordAuthor | Cisplatin | - |
dc.subject.keywordAuthor | Small cell lung carcinoma | - |
dc.subject.keywordAuthor | Korean | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0533
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.